GB Sciences, Inc. (GBLX)
| Market Cap | 14.35M |
| Revenue (ttm) | 1.34M |
| Net Income (ttm) | -11.87M |
| Shares Out | 280.97M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 23 |
| Last Price | $0.0489 |
| Previous Close | $0.0500 |
| Change ($) | -0.0011 |
| Change (%) | -2.20% |
| Day's Open | 0.0510 |
| Day's Range | 0.0436 - 0.0520 |
| Day's Volume | 158,535 |
| 52-Week Range | 0.0250 - 0.1300 |
The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc. LAS VEGAS, NV / ACCESSWIRE / June 17, 2021 / Dr. Andrea Small-Howard has been promoted to the role of President of GB Sciences, I...
Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM). LAS VEGAS, NV / ACCESSWIRE / April 20, 2021 / GB Sciences, Inc. (...
GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ab...
LAS VEGAS, NV / ACCESSWIRE / March 23, 2021 / GB Sciences, Inc. (OTCQB:GBLX) and its Spanish research partners at the Universidad de Sevilla (USE) are pleased to announce the publication of a new scient...
LAS VEGAS, NV / ACCESSWIRE / January 12, 2021 / GB Sciences, Inc. (OTCQB:GBLX) completed the sale of its remaining interest in GB Sciences Louisiana LLC ("GBSLA") on December 16, 2020. In November 2019,...
About GBLX
GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
| Industry Biotechnology | |
| CEO John Poss | Employees 23 |
| Stock Exchange OTCMKTS | Ticker Symbol GBLX |
Financial Performance
In 2019, GB Sciences's revenue was $3.12 million, a decrease of -9.67% compared to the previous year's $3.45 million. Losses were -$12.37 million, -47.69% less than in 2018.